Outcome of Infants Exposed to Olanzapine During Breastfeeding
Outcome of Infants Exposed to Olanzapine During Breastfeeding
复制标题
DOI：
10.1089/bfm.2010.0027
复制
发表时间：
2011-04-01
影响因子：
2.7
通讯作者：
Klinger, Gil
中科院分区：
文献类型：
--
作者：
Gilad, Oded;Merlob, Paul;Klinger, Gil
目的：本研究评估了哺乳期间接触奥氮平的婴儿的结果。方法：采用前瞻性、对照观察性研究设计。就母乳喂养期间使用奥氮平问题联系贝林森畸形学信息服务中心的母亲进行了电话采访。获得了有关哺乳期、新生儿症状和 1-2 岁结局的数据。比较母婴组。将服用奥氮平的母乳喂养母亲 (n = 22) 与继续服用奥氮平但不进行母乳喂养的两个对照组母亲 (n = 15) 以及使用已知在哺乳期间安全的药物的母乳喂养母亲 (n = 51) 进行比较。结果：对 70 名妇女中的 37 名进行了随访。奥氮平暴露母乳喂养婴儿与对照母乳喂养婴儿的比较显示母乳喂养持续时间相似；然而，在奥氮平暴露母乳喂养组中，提前停止母乳喂养更为常见（22 人中的 5 人对 51 人中无一人，p = 0.02）。暴露于奥氮平的母乳喂养婴儿的不良后果发生率与对照组没有差异。宫内暴露于奥氮平的30名新生儿中，未发现先天性出生缺陷。 30 名接触奥氮平的婴儿中有 6 名出现新生儿症状，而 51 名未接触奥氮平的婴儿中有 2 名出现新生儿症状 (p < 0.05)。 30 名婴儿中有 3 名 (10%) 出现戒断综合征。结论：未发现暴露于奥氮平的母乳喂养婴儿的不良长期后果增加。我们的数据与之前对药物暴露极低的估计相结合，支持接受奥氮平治疗的女性继续母乳喂养。然而，在进行更多长期研究之前，应对通过母乳接触奥氮平的婴儿进行随访。
Objective: This study evaluated the outcome of infants exposed to olanzapine during lactation.Methods: A prospective, controlled observational study design was used. Mothers who contacted Beilinson Teratology Information Service regarding use of olanzapine while breastfeeding were followed by phone interview. Data on lactation, neonatal symptoms, and outcome at the age of 1-2 years were obtained. Mother-infant groups were compared. Mothers breastfeeding while taking olanzapine (n = 22) were compared to two control groups of mothers who continued to take olanzapine but did not breastfeed (n = 15) and to breastfeeding mothers using a drug known to be safe during lactation (n = 51).Results: Follow-up was obtained for 37 of 70 women. Comparison of olanzapine-exposed breastfed versus control breastfed infants showed a similar duration of breastfeeding; however, early discontinuation of breastfeeding was more common in the olanzapine-exposed breastfed group (five of 22 vs. none of 51, p = 0.02). The rate of adverse outcomes in olanzapine-exposed breastfed infants did not differ from those of the control groups. Among the 30 newborns exposed in utero to olanzapine, no congenital birth defects were found. Neonatal symptoms were seen in six of 30 of olanzapine-exposed infants versus two of 51 of nonexposed infants (p < 0.05). A withdrawal syndrome was seen in three of 30 (10%) infants.Conclusions: No increase in adverse long-term outcomes in olanzapine-exposed breastfed infants were found. Our data in conjunction with previous estimates of very low drug exposure support continuation of breastfeeding in women treated with olanzapine. However, until additional long-term studies are available, infants exposed to olanzapine through breastmilk should be followed up.